Asset Details
Do you wish to reserve the book?
Fragment-Based Lead Generation of 5-Phenyl-1 H -pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Fragment-Based Lead Generation of 5-Phenyl-1 H -pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors
Do you wish to request the book?
Fragment-Based Lead Generation of 5-Phenyl-1 H -pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Fragment-Based Lead Generation of 5-Phenyl-1 H -pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors
2018
Overview
FXIa is suggested as a major target for anticoagulant drug discovery because of reduced risk of bleeding. In this paper, we defined 5-phenyl-1
-pyrazole-3-carboxylic acid derivatives as privileged fragments for FXIa inhibitors' lead discovery. After replacing the (
)-3-(5-chloro-2-(1
-tetrazol-1-yl)phenyl)acrylamide moiety in compound
with 5-(3-chlorophenyl)-1
-pyrazole-3-carboxamide, we traveled from FXIa inhibitor
to a scaffold that fused the privileged fragments into a pharmacophore for FXIa inhibitors. Subsequently, we synthesized and assessed the FXIa inhibitory potency of a series of 5-phenyl-1
-pyrazole-3-carboxamide derivatives with different P1, P1' and P2'moiety. Finally, the SAR of them was systematically investigated to afford the lead compound
(FXIa Ki = 90.37 nM, 1.5× aPTT in rabbit plasma = 43.33 μM) which exhibited good in vitro inhibitory potency against FXIa and excellent in vitro coagulation activities. Furthermore, the binding mode of
with FXIa was studied and the results suggest that the 2-methylcyclopropanecarboxamide group of
makes 2 direct hydrogen bonds with Tyr58B and Thr35 in the FXIa backbone, making
binds to FXIa in a highly efficient manner.
